Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Non-Small-Cell Lung Cancer on Tyrosine Kinase Inhibitor

NCT06813664 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT06813664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06813664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Non-Small-Cell Lung Cancer on Tyrosine Kinase Inhibitor
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
April 1, 2028
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic nsclc - non-small cell lung cancer, oligoprogressive metastatic disease